Analysts Set Hikma Pharmaceuticals Plc (LON:HIK) Price Target at $2,544.88
Hikma Pharmaceuticals Plc (LON:HIK) has been given a consensus recommendation of “Buy” by the ten ratings firms that are presently covering the company. Three research analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is GBX 2,544.88 ($33.22).
Several brokerages have issued reports on HIK. Stifel Nicolaus restated a “buy” rating on shares of Hikma Pharmaceuticals Plc in a report on Friday, June 24th. Jefferies Group increased their price target on Hikma Pharmaceuticals Plc from GBX 2,380 ($31.07) to GBX 2,800 ($36.55) and gave the stock a “buy” rating in a report on Tuesday, July 5th. Morgan Stanley began coverage on Hikma Pharmaceuticals Plc in a report on Thursday, July 21st. They issued an “equal weight” rating and a GBX 2,700 ($35.24) price target for the company. Numis Securities Ltd began coverage on Hikma Pharmaceuticals Plc in a report on Friday, July 22nd. They issued an “add” rating and a GBX 2,830 ($36.94) price target for the company. Finally, Barclays PLC restated an “overweight” rating and issued a GBX 2,800 ($36.55) price target on shares of Hikma Pharmaceuticals Plc in a report on Thursday, August 4th.
In related news, insider Al-Husry,Ali purchased 140,000 shares of Hikma Pharmaceuticals Plc stock in a transaction that occurred on Wednesday, August 31st. The stock was purchased at an average cost of GBX 2,150 ($28.06) per share, with a total value of £3,010,000 ($3,928,990.99). Also, insider Said Darwazah purchased 10,000 shares of Hikma Pharmaceuticals Plc stock in a transaction that occurred on Wednesday, September 28th. The shares were bought at an average cost of GBX 2,085 ($27.22) per share, with a total value of £208,500 ($272,157.68).
Shares of Hikma Pharmaceuticals Plc (LON:HIK) opened at 2023.00 on Thursday. Hikma Pharmaceuticals Plc has a one year low of GBX 1,575.00 and a one year high of GBX 2,703.00. The stock’s 50 day moving average price is GBX 2,136.46 and its 200 day moving average price is GBX 2,252.28. The firm’s market capitalization is GBX 4.57 billion.
About Hikma Pharmaceuticals Plc
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company develops, manufactures and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa (MENA) region and Europe.
Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with MarketBeat.com's FREE daily email newsletter.